KRAS and non-small cell lung carcinoma: Therefore, the combination of icotinib and BDMC in a selected population of NSCLC patients with EGFR wild-type and K-ras mutation or Her2 mutation, who often refractory to EGFR-TKIs might represent a valid treatment option that warrants clinical investigation.